.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,680,106

« Back to Dashboard

Claims for Patent: 8,680,106

Title:Methods for treating HCV
Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin.
Inventor(s): Bernstein; Barry M. (Mequon, WI), Menon; Rajeev M. (Buffalo Grove, IL), Khatri; Amit (Waukegan, IL), Mensing; Sven (Mannheim, DE), Dutta; Sandeep (Gurnee, IL), Cohen; Daniel E. (Wilmette, IL), Brun; Scott C. (Green Oaks, IL), Awni; Walid M. (Green Oaks, IL), Dumas; Emily O. (Libertyville, IL), Klein; Cheri E. (Northbrook, IL), Podsadecki; Thomas J. (Chicago, IL)
Assignee: AbbVic Inc. (North Chicago, IL)
Application Number:13/935,983
Patent Claims: 1. A method of treatment for HCV, comprising administering at least two direct acting antiviral agents (DAAs) and ribavirin to an HCV treatment-naive patient infected with HCV genotype 1, wherein said treatment does not include administration of interferon to said patient, and said treatment lasts for 8 weeks, wherein said at least two DAAs comprise Compound 1 ##STR00011## and wherein Compound 1 is administered with ritonavir.

2. The method of claim 1, wherein Compound 1, ritonavir and Compound 4 are co-formulated in a single composition and administered once daily, and Compound 2 is administered twice daily.

3. The method of claim 1, wherein Compound 1 is administered 150 mg once daily together with 100 mg ritonavir once daily, and Compound 4 is administered 25 mg once daily, and Compound 2 is administered 400 mg twice daily.

4. The method of claim 1, wherein said patient is infected with HCV genotype 1a.

5. The method of claim 2, wherein said patient is infected with HCV genotype 1a.

6. A method of treatment for HCV, comprising administering at least two direct acting antiviral agents (DAAs) and ribavirin to an HCV treatment-naive patient infected with HCV genotype 1, wherein said treatment does not include administration of interferon to said patient, and said treatment lasts for 8 weeks, and wherein said at least two DAAs comprise PSI-7977 and GS-5885.

7. The method of claim 6, wherein said two DAAs are administered once daily.

8. The method of claim 6, wherein said two DAAs are co-formulated in a single composition and administered once daily.

9. The method of claim 6, wherein PSI-7977 is administered 400 mg once daily, and GS-5885 is administered 90 mg once daily.

10. The method of claim 6, wherein said patient is infected with HCV genotype 1a.

11. The method of claim 7, wherein said patient is infected with HCV genotype 1a.

12. A method of treatment for HCV, comprising administering at least two direct acting antiviral agents (DAAs) and ribavirin to an HCV treatment-naive patient infected with HCV genotype 1, wherein said treatment does not include administration of interferon to said patient, and said treatment lasts for 8, 9, 10, 11 or 12 weeks, and wherein said at least two DAAs comprise Compound 1, Compound 2 and Compound 4, or said at least two DAAs comprise PSI-7977 and GS-5885.

13. The method of claim 12, wherein said at least two DAAs comprise Compound 1, Compound 2 and Compound 4, and wherein Compound 1 is administered with ritonavir.

14. The method of claim 13, wherein Compound 1, ritonavir and Compound 4 are co-formulated in a single composition and administered once daily, and Compound 2 is administered twice daily.

15. The method of claim 13, wherein Compound 1 is administered 150 mg once daily together with 100 mg ritonavir once daily, and Compound 4 is administered 25 mg once daily, and Compound 2 is administered 400 mg twice daily.

16. The method of claim 13, wherein said patient is infected with HCV genotype 1a.

17. The method of claim 12, wherein said at least two DAAs comprise PSI-7977 and GS-5885.

18. The method of claim 17, wherein said two DAAs are administered once daily.

19. The method of claim 17, wherein said two DAAs are co-formulated in a single composition and administered once daily.

20. The method of claim 17, wherein said patient is infected with HCV genotype 1a.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc